Prestige Consumer Healthcare does not discover new drugs. It owns and markets familiar OTC brands, many acquired from larger healthcare companies, including Monistat, Summer's Eve, Clear Eyes, Debrox, Dramamine, Fleet, Chloraseptic, Luden's, Compound W, DenTek, BC and Goody's, TheraTears, Hydralyte and Breathe Right. It had about 890 employees as of March 31, 2026, and trades on the NYSE as PBH. The company is headquartered in Tarrytown, New York. Prestige Consumer Healthcare was formed in 1996 in Tarrytown, New York, as Prestige Brands Holdings to acquire, revitalize, and distribute trusted over-the-counter (OTC) healthcare brands discarded by major pharmaceutical conglomerates.
Prestige makes money by selling branded OTC healthcare products to retailers (mass merchants, drug stores, grocery, club, dollar and e-commerce) in North America and to pharmacy and retail channels internationally, led by Australia. It reports two segments: North American OTC Healthcare and International OTC Healthcare. Most products are made by third-party contract manufacturers, so the company concentrates on brand marketing, retail execution, regulatory compliance and supply management. Capital spending is low, which turns much of operating profit into free cash flow ($246.4 million in FY2026). That cash funds debt paydown, share repurchases and acquisitions of established OTC brands, the main source of portfolio growth. The 2025 purchase of Pillar5 Pharma, a Clear Eyes supplier, was a partial step away from pure outsourcing to secure eye care capacity.